|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US6222020B1
(en)
|
1987-01-07 |
2001-04-24 |
Imperial Cancer Research Technology Limited |
Antigens derived from the core protein of the human mammary epithelial mucin
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
JPH02500329A
(ja)
|
1987-05-21 |
1990-02-08 |
クリエイテイブ・バイオマリキユールズ・インコーポレーテツド |
ターゲット化多機能蛋白質
|
|
EP0366685B1
(en)
|
1987-06-24 |
1994-10-19 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
JPH0874B2
(ja)
|
1990-07-27 |
1996-01-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
EP0954593A1
(en)
|
1996-07-25 |
1999-11-10 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
|
CA2282300C
(en)
|
1997-02-24 |
2011-08-02 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against muc1 tumor-associated antigen
|
|
DE602004027291D1
(de)
*
|
2003-11-25 |
2010-07-01 |
Us Gov Health & Human Serv |
Mutierte anti-cd22-antikörper und immunkonjugate
|
|
WO2005089777A1
(en)
|
2004-03-15 |
2005-09-29 |
Karaolis David K R |
A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
|
PT2032606E
(pt)
|
2006-05-30 |
2014-02-05 |
Genentech Inc |
Anticorpos e imunoconjugados e respetivas utilizações
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
JP2010500011A
(ja)
|
2006-08-08 |
2010-01-07 |
ガンサー ハートマン |
５’リン酸オリゴヌクレオチドの構造および使用
|
|
SI2170353T1
(sl)
|
2007-05-18 |
2015-09-30 |
Adiu Tide Pharmaceuticals Gmbh |
Fosfatno modificirani oligonukleotidni analogi z imunostimulatorno aktivnostjo
|
|
US8236318B2
(en)
|
2007-11-07 |
2012-08-07 |
Celldex Therapeutics Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
US9738680B2
(en)
|
2008-05-21 |
2017-08-22 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5′ triphosphate oligonucleotide with blunt end and uses thereof
|
|
US8450293B2
(en)
|
2010-08-10 |
2013-05-28 |
Rutgers, The State University Of New Jersey |
Synthesis and characterization of C8 analogs of c-di-GMP
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US9650427B2
(en)
|
2011-07-22 |
2017-05-16 |
Children's Medical Center Corporation |
Modulators of antiviral signaling pathways and therapeutic uses thereof
|
|
AU2012315953A1
(en)
|
2011-09-30 |
2014-04-03 |
Kineta, Inc. |
Anti-viral compounds
|
|
ME03512B
(me)
|
2012-02-06 |
2020-04-20 |
Inhibrx Inc |
Cd47 antitijela i postupci za njihovu upotrebu
|
|
AU2013288932A1
(en)
|
2012-07-09 |
2014-12-11 |
Genentech, Inc. |
Immunoconjugates comprising anti - CD79b antibodies
|
|
CN104582717B
(zh)
*
|
2012-07-19 |
2018-03-13 |
雷德伍德生物科技股份有限公司 |
对cd22有特异性的抗体及其使用方法
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
SG11201502796RA
(en)
|
2012-12-13 |
2015-05-28 |
Aduro Biotech Inc |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
JP2016524593A
(ja)
|
2013-04-29 |
2016-08-18 |
メモリアル スローン−ケタリング キャンサー センター |
セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
|
|
CN105377867B
(zh)
|
2013-05-03 |
2019-11-12 |
加利福尼亚大学董事会 |
I型干扰素的环状二核苷酸诱导
|
|
CU24377B1
(es)
|
2013-05-18 |
2018-12-05 |
Aduro Biotech Inc |
Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
|
|
CA3175360C
(en)
|
2013-05-31 |
2024-05-28 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
CN106061981A
(zh)
|
2013-11-06 |
2016-10-26 |
索尔斯蒂斯生物有限公司 |
具有二硫化物基团的多核苷酸构建体
|
|
US10556024B2
(en)
*
|
2013-11-13 |
2020-02-11 |
Whitehead Institute For Biomedical Research |
18F labeling of proteins using sortases
|
|
JP2016538344A
(ja)
|
2013-11-19 |
2016-12-08 |
ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ |
癌処置としてのｓｔｉｎｇアゴニストの使用
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
US9884876B2
(en)
|
2014-05-09 |
2018-02-06 |
Kineta, Inc. |
Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
|
|
CN107109405A
(zh)
|
2014-06-06 |
2017-08-29 |
索尔斯蒂斯生物有限公司 |
具有生物可逆性和非生物可逆性基团的多核苷酸构建体
|
|
CN106604933B
(zh)
|
2014-07-11 |
2021-08-10 |
文塔纳医疗系统公司 |
抗pd-l1抗体及其诊断用途
|
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
|
US20180134802A1
(en)
|
2016-01-08 |
2018-05-17 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
JP6762030B2
(ja)
|
2014-11-20 |
2020-09-30 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
|
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
|
DK3233882T3
(da)
|
2014-12-16 |
2020-01-27 |
Kayla Therapeutics |
Fluorinerede cykliske dinukleotider til cytokininduktion
|
|
HK1245154A1
(zh)
|
2014-12-30 |
2018-08-24 |
细胞基因公司 |
抗cd47抗体及其用途
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
US10618976B2
(en)
|
2015-06-16 |
2020-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP-α agonist antibody
|
|
WO2017011444A1
(en)
|
2015-07-13 |
2017-01-19 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating b cell cancers
|
|
TW201717968A
(zh)
|
2015-07-14 |
2017-06-01 |
春季銀行製藥公司 |
誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
CN108137641B
(zh)
|
2015-08-13 |
2022-04-01 |
默沙东公司 |
作为sting激动剂的环状双核苷酸化合物
|
|
CN116425875A
(zh)
|
2015-09-18 |
2023-07-14 |
安驰肿瘤公司 |
治疗性cd47抗体
|
|
US9650441B2
(en)
|
2015-09-21 |
2017-05-16 |
Erasmus University Medical Center |
Anti-CD47 antibodies and methods of use
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
EP3386517A4
(en)
|
2015-12-08 |
2019-08-07 |
Solstice Biologics, Ltd. |
POLYNUCLEOTIDE CONSTRUCTS COMPRISING AN AUXILIARY FRACTION RELATED NON-BIOREVERSIBLE TO AN INTERNETOSIDIC PHOSPHATE OR PHOSPHOROTHIOATE
|
|
JP2019513692A
(ja)
|
2016-02-19 |
2019-05-30 |
ジェニスフィア・エルエルシー |
核酸キャリア及び治療上の使用方法
|
|
EP3436031A4
(en)
|
2016-04-01 |
2019-09-18 |
Vycellix, Inc. |
Novel RNA construct and method of use therefor for increasing the therapeutic effects of cytotoxic cells and stem cells
|
|
WO2017196867A1
(en)
|
2016-05-09 |
2017-11-16 |
Igm Biosciences, Inc. |
Anti-pd-l1 antibodies
|
|
WO2017196793A1
(en)
|
2016-05-09 |
2017-11-16 |
Celgene Corporation |
Cd47 antibodies and methods of use thereof
|
|
US10059769B2
(en)
|
2016-06-13 |
2018-08-28 |
I-Mab |
Anti-PD-L1 antibodies and uses thereof
|
|
CN109414500B
(zh)
|
2016-06-13 |
2022-02-25 |
奥美药业有限公司 |
治疗和诊断用pd-l1特异性单克隆抗体
|
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
EP3493845A4
(en)
|
2016-08-03 |
2020-04-15 |
The Board of Trustees of the Leland Stanford Junior University |
INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
CN110325549B
(zh)
|
2016-12-09 |
2024-03-08 |
艾利妥 |
抗SIRPα抗体及其使用方法
|
|
PT3443010T
(pt)
|
2017-02-17 |
2024-10-21 |
Ose Immunotherapeutics |
Novos anticorpos anti-sirpa e suas aplicações terapêuticas
|
|
BR112019021520A2
(pt)
|
2017-04-14 |
2020-08-04 |
Tollnine, Inc. |
oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
|
|
EP3807644A4
(en)
|
2018-06-12 |
2022-07-06 |
Angiex, Inc. |
ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
|
|
AU2019360216A1
(en)
|
2018-10-17 |
2021-05-13 |
Tallac Therapeutics, Inc. |
Immunomodulating polynucleotide conjugates and methods of use
|
|
IL295759A
(en)
|
2020-02-28 |
2022-10-01 |
Tallac Therapeutics Inc |
Transglutaminase mediated coupling
|
|
US20230364255A1
(en)
|
2020-08-18 |
2023-11-16 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|